Age (n=451)

0.001

1.02 (1.01–1.03)

0.853

1.01 (0.99–1.01)

Hospitalization time within the last 3 months (days) (n=451)

0.001

1.01 (1.01–1.02)

0.025

1.01 (1.01–1.02)

Number of comorbidities (n=449)

0.001

1.07 (1.03–1.11)

0.238

0.98 (0.94–1.01)

Types of comorbidities (n=449)

Neuropathy

Yes

0.001

1.76 (1.28–2.41)

0.467

1.14 (0.85–1.54)

No

1

1

Screening for CRE colonization (n=451)

Negative

0.001

1.69 (1.27–2.25)

0.287

1.16 (0.88–1.54)

Positive

1

1

APACHE II score (n=451)

<0.001

1.03 (1.02–1.05)

0.022

1.03 (1.01–1.06)

SOFA score (n=451)

0.008

1.06 (1.01–1.10)

0.042

0.92 (0.85–0.99)

Types of HAI (n=120)

Surgical site infection

Yes

0.010

1.56 (1.27–1.91)

0.007

1.40 (1.10–1.78)

No

1

1

Types of invasive procedures (n=438)

Intubation

Yes

<0.001

3.52 (1.98–6.29)

0.554

1.21 (0.64–2.27)

No

1

1

Central venous catheter

Yes

0.001

2.66 (1.37–5.18)

0.251

0.68 (0.35–1.31)

No

1

1

Arterial catheter

Yes

<0.001

2.34 (1.63–3.37)

0.326

1.28 (0.78–2.07)

No

1

1

Urinary catheterization

Yes

<0.001

6.16 (1.58–23.93)

0.549

1.36 (0.50–3.67)

No

1

1

Types of antibiotics (n=418)

Aminoglycoside

Yes

0.027

1.59 (1.09–2.31)

0.575

0.89 (0.60–1.33)

No

1

1

Peptides

Yes

0.041

1.35 (1.01–1.81)

0.793

0.96 (0.74–1.26)

No

1

1

Oxazolidinones

Yes

0.037

1.39 (1.03–1.88)

0.961

1.01 (0.77–1.32)

No

1

1

Treatment outcome (n=451)

Mitigation

1

1

Unchangeability

0.047

1.51 (1.01–2.26)

0.406

1.18 (0.80–1.76)

Aggravation

<0.001

1.86 (1.36–2.54)

0.083

1.33 (0.96–1.85)

Hospitalization time (days) (n=451)

<0.001

1.01 (1.01–1.02)

<0.001

1.01 (1.01–1.02)